Hypertension management in patients with cardiovascular comorbidities

Lucas Lauder, Felix Mahfoud, Michel Azizi, Deepak L. Bhatt, Sebastian Ewen, Kazuomi Kario, Gianfranco Parati, Patrick Rossignol, Markus P. Schlaich, Koon K. Teo, Raymond R. Townsend, Costas Tsioufis, Michael A. Weber, Thomas Weber, Michael Boehm

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)


Arterial hypertension is a leading cause of death globally. Due to ageing, the rising incidence of obesity, and socioeconomic and environmental changes, its incidence increases worldwide. Hypertension commonly coexists with Type 2 diabetes, obesity, dyslipidaemia, sedentary lifestyle, and smoking leading to risk amplification. Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Guidelines recommend dual- and triple-combination therapies using renin-angiotensin system blockers, calcium channel blockers, and/or a diuretic. Comorbidities often complicate management. New drugs such as angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists improve CV and renal outcomes. Catheter-based renal denervation could offer an alternative treatment option in comorbid hypertension associated with increased sympathetic nerve activity. This review summarises the latest clinical evidence for managing hypertension with CV comorbidities.
Original languageEnglish
Pages (from-to)2066-2077
Number of pages12
JournalEuropean Heart Journal
Issue number23
Early online date7 Nov 2022
Publication statusPublished - 14 Jun 2023


Dive into the research topics of 'Hypertension management in patients with cardiovascular comorbidities'. Together they form a unique fingerprint.

Cite this